6-Dimethylamino-9-(beta-D-arabinofuranosyl)-9H-purine: pharmacokinetics and antiviral activity in simian varicella virus-infected monkeys.
6-Dimethylamino-9-(beta-D-arabinofuranosyl)-9H-purine (ara-DMAP) effectively prevented the development of rash and appreciably reduced viremia in simian varicella virus-infected monkeys. Doses of 100 and 50 mg/kg/day, administered orally, were highly effective. The lowest dose of 20 mg/kg/day was much less effective in preventing moderate viremia. However, the 20 mg/kg/day did prevent the development of rash in two of three monkeys. All three doses of ara-DMAP reduced liver infection as reflected by lower aspartate aminotransferase values in the sera of the African green monkeys. Orally administered ara-DMAP was rapidly absorbed. However, significant variation among individual monkeys in the AUC values, peak plasma levels, and plasma half-lives were observed.
Soike
K F
KF
Tulane Regional Primate Research Center, Tulane University, Covington, LA 70433.
Huang
J L
JL
Lambe
C U
CU
Nelson
D J
DJ
Ellis
M N
MN
Krenitsky
T A
TA
Koszalka
G W
GW
D000284:Administration, Oral; D000818:Animals; D000835:Animals, Wild; D000998:Antiviral Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000097:blood; D002644:Chickenpox / Q000188:drug therapy*; D002522:Chlorocebus aethiops; D004341:Drug Evaluation; D006207:Half-Life; D012062:Relative Biological Effectiveness; D012867:Skin / Q000473:pathology; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D014766:Viremia / Q000188:drug therapy
C075035:6-dimethylaminopurine arabinoside; D000998:Antiviral Agents; D001219:Aspartate Aminotransferases; D014740:Vidarabine